19654-32-1

Basic information

• Product Name: 2,4-DICHLOROBENZYL ISOCYANATE
• Synonyms: 2,4-Dichlorobenzyl isocyanate 98%;2,4-DICHLOROBENZYL ISOCYANATE;2,4-dichloro-1-(isocyanatomethyl)benzene
• CAS NO: 19654-32-1
• Molecular Formula: C₈H₅Cl₂NO
• Molecular Weight: 202.04
• Product Categories: Isocyanates;Nitrogen Compounds;Organic Building Blocks
• Mol File: 19654-32-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 273 °C(lit.)
• Flash Point: >230 °F
• Appearance: White to yellow to light brown/Crystalline Powder
• Density: 1.388 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.0075mmHg at 25°C
• Refractive Index: n20/D 1.565(lit.)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2,4-DICHLOROBENZYL ISOCYANATE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DICHLOROBENZYL ISOCYANATE(19654-32-1)
• EPA Substance Registry System: 2,4-DICHLOROBENZYL ISOCYANATE(19654-32-1)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36
• RIDADR: UN 2206 6.1/PG 3
• WGK Germany: 3
• Hazardous Substances Data: 19654-32-1(Hazardous Substances Data)

Usage

Description

2,4-Dichlorobenzyl isocyanate, also known as 2,4-dichloro-1-(isocyanatomethyl)benzene, is an organic building block that features an isocyanate group. 2,4-DICHLOROBENZYL ISOCYANATE is characterized by its reactivity and potential for use in the synthesis of various chemical products.

Uses

Used in Pharmaceutical Industry:
2,4-Dichlorobenzyl isocyanate is used as a synthetic intermediate for the preparation of N-(2,5-dichlorobenzyl)-1-(4-methoxybenzyl)-4,5-dihydro-1H-imidazol-2-amine, which is a compound with potential applications in the development of pharmaceuticals. The isocyanate group in 2,4-Dichlorobenzyl isocyanate allows for further chemical reactions and modifications, making it a versatile building block in the synthesis of new drug candidates.

InChI:InChI=1/C8H5Cl2NO/c9-7-2-1-6(4-11-5-12)8(10)3-7/h1-3H,4H2

Upstream product

• 6306-60-1 2,4-Dichlorophenylacetonitrile 
• 95-00-1 2,4-dichloro-benzenemethanamine 
• 20443-99-6 2,4-dichlorobenzyl bromide 
• 1777-82-8 (2,4-dichlorophenyl)methanol 
• 19719-28-9 2,4-dichlorophenylacetic acid 
• 53056-20-5 2,4-dichlorophenylacetyl chloride 

Downstream Products

• 1431868-63-1 tert-butyl 1-(2,4-dichlorobenzylcarbamoyl)-1,6-diazaspiro[3.3]heptane-6-carboxylate 
• 1434640-65-9 N-(2,4-dichlorobenzyl)-1-(4-methoxybenzyl)-4,5-dihydro-1H-imidazol-2-amine 
• 1431868-39-1 N-(2,4-dichlorobenzyl)-1-(4-fluorophenylsulfonyl)-1,6-diazaspiro[3.3]heptane-6-carboxamide 
• 1431868-35-7 6-benzoyl-2,6-diaza-spiro[3.3]heptane-2-carboxylic acid 2,4-dichloro-benzylamide 
• 1431868-57-3 2,6-diaza-spiro[3.3]heptane-2-carboxylic acid 2,4-dichloro-benzylamide 
• 1431868-56-2 6-(2,4-dichloro-benzylcarbamoyl)-2,6-diaza-spiro[3.3]heptane-2-carboxylic acid tert-butyl ester 
• 1206686-43-2 N-[(2,4-dichlorophenyl)methyl]-N'-[(4-{4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}bicyclo[2.2.2]oct-1-yl)methyl]urea 
• 1206687-02-6 N'-[(2,4-dichlorophenyl)methyl]-N-methyl-N-[(4-{4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}bicyclo[2.2.2]oct-1-yl)methyl]urea 
• 950649-16-8 4-(4-carboxyethylphenyloxy)-piperidine-1-carboxylic acid 2,4-dichloro-benzylamide 
• 581811-53-2 N-(2,4-dichlorobenzyl)-N'-(3-methyl-5-isoquinolinyl)urea 
• 735331-13-2 N-(2,4-dichlorobenzyl)-N'-(1-methyl-1H-indazol-4-yl)urea 
• 326920-08-5 N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2,4-dichlorobenzyl)urea 
• 581810-37-9 N-(8-bromoisoquinolin-5-yl)-N'-(2,4-dichlorobenzyl)urea 
• 852241-29-3 N-(2,4-dichlorobenzyl)-N'-(3-methyl-5-isoquinolinyl)urea hydrochloride 

Relevant articles and documents

Design and synthesis of Rho kinase inhibitors (II)

In a previous study, we identified several structurally unrelated scaffolds of the Rho kinase inhibitor using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. 1H-Indazole is one of the candidate scaffolds on which a new series of potent Rho kinase inhibitors could be developed. In this study, the detailed structure-activity relationship of 1H-indazole analogues was studied. During this study, we found that the cell-free enzyme inhibitory potential of Rho kinase inhibitors having the 1H-indazole scaffold did not necessarily correlate with their inhibitory potential toward the chemotaxis of cultured cells. The choice of the linker substructure was shown to be an important factor for the 1H-indazole analogues to inhibit the chemotaxis of cells. Optimization of the 1H-indazole inhibitors with respect to the in vitro inhibition of monocyte chemotaxis induced by MCP-1 was carried out. The inhibitory potential was improved both in the cell-free enzyme assay and in the chemotaxis assay.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Synthesis, selective aldose reductase inhibitory profile and antihyperglycaemic potential of certain parabanic acid derivatives

Synthesis and aldose reductase inhibitory profile of certain parabanic acid derivatives 1a-p is described. Also, the antihyperglycaemic potential of these compounds was studied. The most active inhibitors in this series were compounds 1 g, 1p, and 1o which showed inhibitory activity, 36.6, 90 and 91% respectively, at concentration 1 × 10-4. Their IC50 were 2 × 10-6, 7.5 × 10-8 and 5 × 10-8, respectively. Compound 1o exhibited pronounced antihyperglycaemic effect.